|
Selected
later-stage compounds in development:
Abatacept,
a compound in Phase III clinical trials for the potential treatment
of rheumatoid arthritis.
Edifoligide,
in Phase III for the potential prevention of vein graft failure
following coronary artery bypass graft and peripheral artery bypass
graft surgery.
Entecavir,
a compound in Phase III for the potential treatment of hepatitis
B.
Ixabepilone,
an epothilone in Phase III for the potential treatment of cancer.
Javlor®
(vinflunine), a compound in Phase III for the potential treatment
of cancer.
LEA29Y,
an agent in Phase II for the potential treatment to prevent solid
organ transplant rejection.
MDX-010,
an investigational anticancer compound in Phase III.
Muraglitazar,
a dual PPAR agonist in Phase III for potential treatment of type
2 diabetes. Backup compound in development.
Razaxaban,
a factor Xa inhibitor in Phase II for the potential treatment of
venous thrombosis. Backup compounds in development.
Saxagliptin,
an oral compound in Phase II for the potential treatment of diabetes.
Backup compound in development.
Last
updated November 10, 2004
|
